Provided by Tiger Fintech (Singapore) Pte. Ltd.

Abbott Laboratories

123.67
+3.162.62%
Post-market: 123.800.1300+0.11%19:59 EDT
Volume:19.57M
Turnover:2.43B
Market Cap:215.17B
PE:16.06
High:125.63
Open:122.63
Low:122.27
Close:120.51
Loading ...

Who’s backing who? Every newspaper’s pick for prime minister

The Sydney Morning Herald
·
02 May

MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races

PR Newswire
·
01 May

Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession

Insider Monkey
·
01 May

Abbott Agrees to Integrate Libre Data With Epic's Record System

MT Newswires Live
·
30 Apr

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

PR Newswire
·
29 Apr

Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials

Simply Wall St.
·
29 Apr

PBH or ABT: Which Is the Better Value Stock Right Now?

Zacks
·
28 Apr

3 Dividend Stocks to Buy and Hold for the Next Decade

Motley Fool
·
28 Apr

The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic

Zacks
·
28 Apr

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Simply Wall St.
·
28 Apr

Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance

MT Newswires Live
·
28 Apr

Abbott Laboratories: Strategic Advancements and Market Positioning with Volt PFA Platform Drive Buy Rating

TIPRANKS
·
28 Apr

Abbott announces new AVEIR data, initiates trial for pacing technology

TIPRANKS
·
28 Apr

Abbott announces new data from its Volt CE Mark Study

TIPRANKS
·
28 Apr

BRIEF-Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt™ Pfa System For Patients With Afib

Reuters
·
27 Apr

Abbott Laboratories - Volt Pfa System Shows Strong 12-Month Results

THOMSON REUTERS
·
27 Apr

Abbott Laboratories - Only 2.7% Experienced Safety Endpoint Event After 12 Months

THOMSON REUTERS
·
27 Apr

Abbott Laboratories - 83.5% Paf and 58.1% Persaf Patients Arrhythmia-Free After 12 Months

THOMSON REUTERS
·
27 Apr

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ Pfa System for Patients With Afib

THOMSON REUTERS
·
27 Apr

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

PR Newswire
·
27 Apr